Cover Image
市場調查報告書

結腸癌:開發中產品分析

Colon Carcinoma - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 265424
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
結腸癌:開發中產品分析 Colon Carcinoma - Pipeline Review, H2 2014
出版日期: 2014年08月25日 內容資訊: 英文 53 Pages
簡介

結腸癌是消化器官下部、大腸(結腸)的癌症。常見的症狀有排便習慣的變化、連續數天的下痢、便秘或是細便、直腸出血、黑便或是糞便潛血、肌肉痙攣或腹痛,虛弱及疲勞。大腸癌的治療選擇有化療、手術及放射線治療。

本報告提供結腸癌的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介等相關的系統性資訊。

目錄

簡介

結腸癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Philogen S.p.A.
  • AIMM Therapeutics B.V.
  • Synergys Biotherapeutics, Inc

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品的說明·作用機制·R&D進展)

  • CIGB-247 Vaccine
  • Antibody for Oncology
  • Small Molecules to Inhibit Tubulin for Oncology
  • Monoclonal Antibodies for Gastrointestinal Diseases
  • Anti-EGFR-ATEP
  • Methoxynaphthylfenoterol
  • Salmonella Based Cancer Vaccine
  • IL-2 Therapy
  • Adhesio-mAb
  • Anti-MFG-E8 Mab
  • F8IL-4
  • Antibody to Inhibit Rspo2 and Rspo3 for Oncology
  • DR5-Receptor Specific TRAIL Mutant Protein

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5384IDB

Summary

Global Markets Direct's, 'Colon Carcinoma - Pipeline Review, H2 2014', provides an overview of the Colon Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colon Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Colon Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Colon Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Colon Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Colon Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Colon Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Colon Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Colon Carcinoma - Overview
    • Pipeline Products for Colon Carcinoma - Comparative Analysis
  • Colon Carcinoma - Therapeutics under Development by Companies
  • Colon Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Colon Carcinoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Colon Carcinoma - Products under Development by Companies
  • Colon Carcinoma - Products under Investigation by Universities/Institutes
  • Colon Carcinoma - Companies Involved in Therapeutics Development
    • Aposense Ltd.
    • Teva Pharmaceutical Industries Limited
    • Patrys Limited
    • Philogen S.p.A.
    • AIMM Therapeutics B.V.
  • Colon Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CEP-37250 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAT-LM1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATT-11T - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CIGB-247 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Colon Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methoxynaphthylfenoterol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Lymphoma and Colon Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Activate IL-2 Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Adhesio-mAb - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Anti-MFG-E8 Mab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F8IL-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Colon Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit Rspo2 and Rspo3 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Colon Carcinoma - Recent Pipeline Updates
  • Colon Carcinoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Colon Carcinoma, H2 2014
  • Number of Products under Development for Colon Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Colon Carcinoma - Pipeline by Aposense Ltd., H2 2014
  • Colon Carcinoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014
  • Colon Carcinoma - Pipeline by Patrys Limited, H2 2014
  • Colon Carcinoma - Pipeline by Philogen S.p.A., H2 2014
  • Colon Carcinoma - Pipeline by AIMM Therapeutics B.V., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Colon Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014
  • Colon Carcinoma - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Colon Carcinoma, H2 2014
  • Number of Products under Development for Colon Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top